The global pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.5% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the Rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of global pancreatic cancer diagnostics market are:
Rise in prevalence and incidence of pancreatic cancer
Increase in awareness about the pancreatic cancer diagnostics
Market Players:
Some of the major players operating in the global pancreatic cancer diagnostics market are:
Canon Medical Systems ANZ Pty Limited.
Koninklijke Philips N.V.
Siemens Healthcare Private Limited
Grail
Myriad Genetics, Inc.
BD
Boditech Med Inc.
Abbott
FUJIFILM Holdings America Corporation
Agilent Technologies, Inc.
Thermo Fisher Scientific
QIAGEN
MP BIOMEDICALS
Laboratory Corporation of America Holdings
CTK Biotech, Inc.
AccuBioTech Co., Ltd.
DiaSource
Setia Scientific Solution
Creative Biolabs
Meridian Life Science, Inc.
Lee Biosolutions, Inc
TABLE OF CONTENTS
1 INTRODUCTION 92
- 1.1 OBJECTIVES OF THE STUDY 92
- 1.2 MARKET DEFINITION 92
- 1.3 OVERVIEW OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 92
- 1.4 CURRENCY AND PRICING 95
- 1.5 LIMITATIONS 95
- 1.6 MARKETS COVERED 95
2 MARKET SEGMENTATION 99
- 2.1 MARKETS COVERED 99
- 2.2 GEOGRAPHICAL SCOPE 100
- 2.3 YEARS CONSIDERED FOR THE STUDY 101
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 102
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 105
- 2.6 MULTIVARIATE MODELLING 106
- 2.7 MARKET END USER COVERAGE GRID 107
- 2.8 PRODUCT LIFELINE CURVE 108
- 2.9 DBMR MARKET POSITION GRID 109
- 2.10 VENDOR SHARE ANALYSIS 110
- 2.11 SECONDARY SOURCES 111
- 2.12 ASSUMPTIONS 111
3 EXECUTIVE SUMMARY 112
4 PREMIUM INSIGHTS 115
- 4.1 PESTEL ANALYSIS 118
- 4.2 PORTER'S FIVE FORCES MODEL 119
5 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 120
6 EPIDEMIOLOGY 122
7 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 123
8 MARKET OVERVIEW 126
- 8.1 DRIVERS 128
- 8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 128
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 128
- 8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 129
- 8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 129
- 8.2 RESTRAINTS 130
- 8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 130
- 8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 130
- 8.3 OPPORTUNITIES 131
- 8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 131
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 132
- 8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 132
- 8.4 CHALLENGES 133
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 133
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 133
9 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 134
- 9.1 OVERVIEW 135
- 9.2 IMAGING TEST 138
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 139
- 9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 139
- 9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 139
- 9.2.2.2 MR ANGIOGRAPHY (MRA) 140
- 9.2.3 ULTRASOUND 140
- 9.2.3.1 ABDOMINAL ULTRASOUND 140
- 9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 140
- 9.2.4 CHOLANGIOPANCREATOGRAPHY 140
- 9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 141
- 9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 141
- 9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 141
- 9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 141
- 9.2.6 OTHERS 141
- 9.3 BIOPSY 142
- 9.3.1 CT-GUIDED NEEDLE BIOPSY 143
- 9.3.2 FINE NEEDLE ASPIRATION (FNA) 143
- 9.3.3 CORE NEEDLE BIOPSY 143
- 9.3.4 OTHERS 143
- 9.4 BLOOD TEST 143
- 9.4.1 LIVER FUNCTION TEST 144
- 9.4.2 TUMOR MARKER 144
- 9.4.2.1 CA 19-9 BIOMARKER TEST 145
- 9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 145
- 9.4.2.3 CA 50 MARKER TEST 145
- 9.4.2.4 OTHERS 145
- 9.4.3 OTHERS 145
- 9.5 GENOMIC TEST 146
- 9.6 OTHERS 147
10 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 148
- 10.1 OVERVIEW 149
- 10.2 STAGE IV 152
- 10.3 STAGE III 152
- 10.4 STAGE II 153
- 10.4.1 STAGE IIA 154
- 10.4.2 STAGE IIB 154
- 10.5 STAGE I 154
- 10.5.1 STAGE IA 155
- 10.5.2 STAGE IB 155
- 10.6 STAGE 0 156
11 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 157
- 11.1 OVERVIEW 158
- 11.2 EXOCRINE TUMORS 161
- 11.2.1 INSTRUMENT-BASED PRODUCTS 162
- 11.2.2 PLATFORM-BASED PRODUCTS 162
- 11.2.3 KITS AND REAGENTS 162
- 11.2.4 OTHER CONSUMABLES 162
- 11.3 NEUROENDOCRINE TUMORS 162
- 11.3.1 INSTRUMENT-BASED PRODUCTS 163
- 11.3.2 PLATFORM-BASED PRODUCTS 163
- 11.3.3 KITS AND REAGENTS 164
- 11.3.4 OTHER CONSUMABLES 164
12 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 165
- 12.1 OVERVIEW 166
- 12.2 INSTRUMENT-BASED PRODUCTS 169
- 12.2.1 IMAGING 170
- 12.2.2 BIOPSY 170
- 12.3 PLATFORM-BASED PRODUCTS 170
- 12.3.1 NEXT-GENERATION SEQUENCING 171
- 12.3.2 MICROARRAYS 171
- 12.3.3 PCR 171
- 12.3.4 OTHERS 172
- 12.4 KITS AND REAGENTS 172
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 173
- 12.4.1.1 ELISA TEST KITS 173
- 12.4.1.2 CASETTE TEST KITS 173
- 12.4.1.3 OTHERS 173
- 12.4.2 CEA PANCREATIC CANCER TEST KITS 174
- 12.4.2.1 ELISA TEST KITS 174
- 12.4.2.2 CASETTE TEST KITS 174
- 12.4.2.3 OTHERS 174
- 12.5 OTHER CONSUMABLES 174
13 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 176
- 13.1 OVERVIEW 177
- 13.2 FLUORESCENT IN SITU HYBRIDIZATION 180
- 13.3 NEXT GENERATION SEQUENCING 181
- 13.4 FLUORIMMUNOASSAY 182
- 13.5 COMPARATIVE GENOMIC HYBRIDIZATION 183
- 13.6 IMMUNOHISTOCHEMICAL 184
- 13.7 OTHERS 185
14 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 186
- 14.1 OVERVIEW 187
- 14.2 SCREENING 190
- 14.2.1 INSTRUMENT-BASED PRODUCTS 191
- 14.2.2 PLATFORM-BASED PRODUCTS 191
- 14.2.3 KITS AND REAGENTS 191
- 14.2.4 OTHER CONSUMABLES 191
- 14.3 DIAGNOSTIC AND PREDICTIVE 191
- 14.3.1 INSTRUMENT-BASED PRODUCTS 192
- 14.3.2 PLATFORM-BASED PRODUCTS 192
- 14.3.3 KITS AND REAGENTS 192
- 14.3.4 OTHER CONSUMABLES 192
- 14.4 PROGNOSTIC 193
- 14.4.1 INSTRUMENT-BASED PRODUCTS 194
- 14.4.2 PLATFORM-BASED PRODUCTS 194
- 14.4.3 KITS AND REAGENTS 194
- 14.4.4 OTHER CONSUMABLES 194
- 14.5 RESEARCH 194
- 14.5.1 INSTRUMENT-BASED PRODUCTS 195
- 14.5.2 PLATFORM-BASED PRODUCTS 195
- 14.5.3 KITS AND REAGENTS 195
- 14.5.4 OTHER CONSUMABLES 195
15 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 196
- 15.1 OVERVIEW 197
- 15.2 HOSPITALS 200
- 15.3 DIAGNOSTIC CENTERS 200
- 15.4 CANCER RESEARCH CENTERS 201
- 15.5 ACADEMIC INSTITUTES 202
- 15.6 AMBULATORY SURGICAL CENTERS 203
- 15.7 OTHERS 204
16 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 205
- 16.1 OVERVIEW 206
- 16.2 DIRECT TENDER 209
- 16.3 RETAIL SALES 210
- 16.4 OTHERS 211
17 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 212
- 17.1 OVERVIEW 213
- 17.2 NORTH AMERICA 219
- 17.2.1 U.S. 233
- 17.2.2 CANADA 242
- 17.2.3 MEXICO 251
- 17.3 EUROPE 260
- 17.3.1 GERMANY 275
- 17.3.2 FRANCE 284
- 17.3.3 UNITED KINGDOM 293
- 17.3.4 ITALY 302
- 17.3.5 SPAIN 311
- 17.3.6 RUSSIA 320
- 17.3.7 NETHERLANDS 329
- 17.3.8 POLAND 338
- 17.3.9 SWITZERLAND 347
- 17.3.10 BELGIUM 356
- 17.3.11 SWEDEN 365
- 17.3.12 NORWAY 374
- 17.3.13 DENMARK 383
- 17.3.14 FINLAND 392
- 17.3.15 TURKEY 401
- 17.3.16 REST OF EUROPE 410
- 17.4 ASIA-PACIFIC 411
- 17.4.1 CHINA 424
- 17.4.2 JAPAN 432
- 17.4.3 INDIA 440
- 17.4.4 SOUTH KOREA 448
- 17.4.5 AUSTRALIA 456
- 17.4.6 TAIWAN 464
- 17.4.7 NEW ZEALAND 472
- 17.4.8 INDONESIA 480
- 17.4.9 THAILAND 488
- 17.4.10 PHILIPPINES 496
- 17.4.11 MALAYSIA 504
- 17.4.12 VIETNAM 512
- 17.4.13 SINGAPORE 520
- 17.4.14 REST OF ASIA-PACIFIC 528
- 17.5 SOUTH AMERICA 529
- 17.5.1 BRAZIL 542
- 17.5.2 ARGENTINA 550
- 17.5.3 REST OF SOUTH AMERICA 558
- 17.6 MIDDLE EAST AND AFRICA 559
- 17.6.1 SOUTH AFRICA 574
- 17.6.2 SAUDI ARABIA 583
- 17.6.3 BAHRAIN 592
- 17.6.4 UAE 601
- 17.6.5 EGYPT 610
- 17.6.6 ISRAEL 619
- 17.6.7 KUWAIT 628
- 17.6.8 OMAN 637
- 17.6.9 QATAR 646
- 17.6.10 REST OF MIDDLE EAST AND AFRICA 655
18 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 656
- 18.1 COMPANY SHARE ANALYSIS: GLOBAL 656
- 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 657
- 18.3 COMPANY SHARE ANALYSIS: EUROPE 658
- 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 659
19 SWOT ANALYSIS 660
20 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 661
- 20.1 CANON MEDICAL SYSTEMS CORPORATION 661
- 20.1.1 COMPANY SNAPSHOT 661
- 20.1.2 REVENUE ANALYSIS 661
- 20.1.3 COMPANY SHARE ANALYSIS 662
- 20.1.4 PRODUCT PORTFOLIO 662
- 20.1.5 RECENT DEVELOPMENT 662
- 20.2 KONINKLIJKE PHILIPS N.V. 663
- 20.2.1 COMPANY SNAPSHOT 663
- 20.2.2 REVENUE ANALYSIS 663
- 20.2.3 COMPANY SHARE ANALYSIS 664
- 20.2.4 PRODUCT PORTFOLIO 664
- 20.2.5 RECENT DEVELOPMENTS 664
- 20.3 SIEMENS HEALTHCARE GMBH 666
- 20.3.1 COMPANY SNAPSHOT 666
- 20.3.2 REVENUE ANALYSIS 666
- 20.3.3 COMPANY SHARE ANALYSIS 667
- 20.3.4 PRODUCT PORTFOLIO 667
- 20.3.5 RECENT DEVELOPMENT 668
- 20.4 GRAIL 669
- 20.4.1 COMPANY PROFILE 669
- 20.4.2 COMPANY SHARE ANALYSIS 669
- 20.4.3 PRODUCT PORTFOLIO 670
- 20.4.4 RECENT DEVELOPMENT 670
- 20.5 MYRIAD GENETICS, INC. 671
- 20.5.1 COMPANY SNAPSHOT 671
- 20.5.2 REVENUE ANALYSIS 671
- 20.5.3 COMPANY SHARE ANALYSIS 672
- 20.5.4 PRODUCT PORTFOLIO 672
- 20.5.5 RECENT DEVELOPMENT 672